A recent meta-analysis scrutinized variations in the liver function tests, specifically alanine transaminase (ALT), aspartate transaminase (AST), and gamma-glutamyl transpeptidase (γ-GGT), in 22 studies with 2345 NAFLD patients treated with statins. Here, GPT is linked to metabolic dysfunction-associated steatotic liver disease.